UroGen Pharma Ltd.
$24.92
▼
-0.63%
2026-04-21 10:03:00
www.urogen.com
NGM: URGN
Explore UroGen Pharma Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.21 B
Current Price
$24.92
52W High / Low
$30 / $3.42
Stock P/E
—
Book Value
$-2.18
Dividend Yield
—
ROCE
-81.06%
ROE
268.63%
Face Value
—
EPS
$-3.19
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
291
Beta
1.44
Debt / Equity
-1.22
Current Ratio
4.01
Quick Ratio
3.65
Forward P/E
20.74
Price / Sales
9.56
Enterprise Value
$1.06 B
EV / EBITDA
-8.51
EV / Revenue
9.65
Rating
Strong Buy
Target Price
$35.62
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Exicure, Inc. | $3.77 | — | $22.85 M | — | -99.65% | -92.47% | $12.65 / $3.1 | $0.62 |
| 2. | Invivyd, Inc. | $1.68 | — | $492.08 M | — | -22.89% | -33.97% | $3.07 / $0.46 | $0.86 |
| 3. | Oramed Pharmaceuticals Inc. | $3.83 | 3.45 | $151.27 M | 0% | -7.12% | 37.1% | $3.96 / $1.98 | $4.98 |
| 4. | Gain Therapeutics, Inc. | $2.12 | — | $89.98 M | — | -96.12% | -1.56% | $4.34 / $1.41 | $0.44 |
| 5. | Nkarta, Inc. | $3.49 | — | $247.38 M | — | -31.94% | -28.9% | $3.48 / $1.63 | $4.39 |
| 6. | Immunic, Inc. | $0.95 | — | $124.59 M | — | 1572.16% | -16.53% | $1.51 / $0.51 | $-0.06 |
| 7. | Anavex Life Sciences Corp. | $3.65 | — | $338.25 M | — | -54.15% | -33.63% | $13.99 / $2.61 | $1.37 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 37.84 M | 27.48 M | 24.21 M | 20.25 M | 24.57 M | — |
| Operating Profit | -19.11 M | -27.39 M | -41.45 M | -36.91 M | -27.66 M | — |
| Net Profit | -26.36 M | -33.35 M | -49.94 M | -43.84 M | -37.51 M | — |
| EPS in Rs | -0.54 | -0.68 | -1.03 | -0.9 | -0.77 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 109.79 M | 90.4 M | 82.71 M | 64.36 M |
| Operating Profit | -124.86 M | -96.78 M | -65.54 M | -79.04 M |
| Net Profit | -153.49 M | -126.87 M | -102.24 M | -109.78 M |
| EPS in Rs | -3.15 | -2.61 | -2.1 | -2.26 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 200.46 M | 285.71 M | 178.31 M | 135.62 M |
| Total Liabilities | 305.93 M | 294.51 M | 243.52 M | 224.98 M |
| Equity | -105.47 M | -8.8 M | -65.21 M | -89.36 M |
| Current Assets | 186.02 M | 276.13 M | 169.19 M | 128.91 M |
| Current Liabilities | 46.42 M | 45.95 M | 31.21 M | 23.92 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -162.44 M | -96.77 M | -76.38 M | -87.56 M |
| Investing CF | 61.56 M | -20.61 M | -0.95 M | 1.06 M |
| Financing CF | 39.92 M | 194.62 M | 116.93 M | 97.13 M |
| Free CF | -162.73 M | -97.06 M | -76.57 M | -87.81 M |
| Capex | -0.29 M | -0.29 M | -0.19 M | -0.25 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 9.29% | 28.52% | — | — |
| Earnings Growth % | -24.09% | 6.87% | — | — |
| Profit Margin % | -140.35% | -123.61% | -170.58% | — |
| Operating Margin % | -107.06% | -79.23% | -122.82% | — |
| Gross Margin % | 90.18% | 88.68% | 88.11% | — |
| EBITDA Margin % | -122.05% | -99.02% | -151.92% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.